admin
Recurrence-free survival after sentinel node biopsy in melanoma?
Br J Dermatol. 2006 Sep; 155(3): 631-2Hayes AJ, Thomas JM
Sydney Melanoma Unit patients in breach of multicentre selective lymphadenectomy trial protocol?
ANZ J Surg. 2006 Nov; 76(11): 1038-9; author reply 1039-40Thomas JM
Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Ann Surg Oncol. 2007 Jan; 14(1): 230-8Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM
BACKGROUND: Isolated limb perfusion (ILP) with melphalan is used in the treatment of advanced in-transit melanoma but has no real efficacy for irresectable soft tissue sarcomas arising in the extremities. The addition of tumor necrosis factor (TNF)-alpha may increase response rates for [...]
Incidence, mortality and survival in cutaneous melanoma.
J Plast Reconstr Aesthet Surg. 2007; 60(1): 32-40Giblin AV, Thomas JM
Cutaneous melanoma remains a challenge despite increased levels of awareness, education and targeted health policies. Worldwide incidence rates for cutaneous melanoma have risen faster than those for any other malignancy in Caucasian populations over the last 30 years. Despite improving survival rates (defined as the [...]
Sentinel-node biopsy in melanoma.
N Engl J Med. 2007 Jan 25; 356(4): 418; author reply 419-21Thomas JM
Sentinel lymph node biopsy as the standard of care for cutaneous melanoma.
Clin Adv Hematol Oncol. 2007 Jun; 5(6): 483-90Sondak VK, Zager JS, Messina JL, Thomas JM
Clear cell sarcoma (melanoma of soft parts): The Royal Marsden Hospital experience.
Eur J Surg Oncol. 2007 Nov 26; Clark MA, Johnson MB, Thway K, Fisher C, Thomas JM, Hayes AJ
INTRODUCTION: Clear cell sarcoma (CCS) is a rare tumour with a propensity for local recurrence and nodal metastasis. About 300 cases have been reported, thus further clarification regarding the course and outcome of the disease is required. [...]
Prognostic false-positivity of the sentinel node in melanoma.
Nat Clin Pract Oncol. 2008 Jan; 5(1): 18-23Thomas JM
It is a basic tenet of the sentinel lymph-node biopsy procedure that all positive sentinel lymph nodes will inevitably progress to palpable nodal recurrence if not removed. Comparison of survival is, therefore, considered permissible among patients with positive sentinel lymph nodes who undergo early lymphadenectomy with that [...]
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma (Br J Surg 2007; 94: 1293-1299).
Br J Surg. 2008 May; 95(5): 664; author reply 664-5Thomas JM, Hayes A
Sentinel lymph node biopsy in malignant melanoma.
BMJ. 2008 Apr 26; 336(7650): 902-3Thomas JM
When melanoma spreads, it invariably does so by the lymphatic system. The first lymph node to be affected is called the sentinel node, and this node can be identified by injecting dye and a radioactive tracer at the primary tumour site. During sentinel lymph node biopsy, the sentinel node [...]